386: The high stakes for Huntington's patients

What It Covers

Patient advocate Lauren Holder discusses Huntington's disease and the FDA's reversal on UniCure's gene therapy, which showed 75% slowing of disease progression over three years. The agency initially accepted the trial design with external controls, then rejected it months later, devastating a community with twice the general population's suicide rate.

Key Questions Answered

• •FDA Guidance Reversal: UniCure designed its Huntington's gene therapy trial based on FDA guidance accepting external control arms instead of sham brain surgery. After three years of data showing 75% disease slowing, FDA reversed position and rejected the submission approach, creating uncertainty about whether future developers can trust agency guidance for rare disease trials.
• •Sham Surgery Ethics: Placebo-controlled trials remain important for drug development, but sham brain surgery poses unique ethical problems in neurodegenerative diseases. Europe rejected sham procedures for UniCure's trial due to risks of brain inflammation and neurodegeneration. Patients face a narrow treatment window where their brains remain healthy enough to benefit from intervention.
• •Huntington's Symptom Complexity: Huntington's disease extends beyond movement disorders to include executive dysfunction, social anxiety, depression, short-term memory loss, and attention deficits that appear years before physical symptoms. Only 20% of patients experience behavioral symptoms, and disease presentation varies dramatically between individuals, requiring individualized treatment approaches rather than one-size-fits-all protocols.
• •Treatment Window Urgency: Prodromal Huntington's patients have a limited timeframe when their brains remain healthy enough to benefit from gene therapy. Additional three to five year delays for new trials would eliminate treatment eligibility for current prodromal patients, who face progressive cognitive decline that prevents them from processing information and maintaining insight as disease advances.
• •Rare Disease Approval Inconsistency: Cancer treatments receive faster approval pathways than neurodegenerative disease therapies despite comparable patient urgency. The FDA lacks consistency across disease categories, with cell and gene therapy developers experiencing setbacks despite agency officials publicly stating their commitment to accelerate rare disease treatment development and approval processes for conditions with no existing disease-modifying options.